Frankfurt
15.09.26 | 08:03
9,550 Euro
-0,52 % -0,050
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,370 | 10,060 | 15.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.09. | Original-Research: Nexstim (von NuWays AG): BUY | 424 | EQS Group (EN) | Original-Research: Nexstim - from NuWays AG
02.09.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content... ► Artikel lesen | |
| 02.09. | Stimulating growth with surgical accuracy; INITIATE with BUY: We initate Nexstim coverage with a BUY ... | 404 | NuWays | Nexstim is a Finnish MedTech company and a global leader in navigated transcranial magnetic stimulation (nTMS) technology. With nTMS, Nexstim helps (i) surgeons preserve patients' motor and speech cortices... ► Artikel lesen | |
| 21.08. | Nexstim Oyj: Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer | 182 | GlobeNewswire (Europe) | Press release, Helsinki, 21 August 2026 at 9 AM (EEST)
Nexstim Receives NBS 6 System Order for a European hospital and existing Nexstim customer
Nexstim Plc ("Nexstim" or "Company") has received an... ► Artikel lesen | |
| 14.08. | Nexstim meldet Umsatzwachstum für H1 2026 und Rekord-Auftragsbestand | 2 | Investing.com Deutsch | ||
| 14.08. | Nexstim Oyj: Nexstim Plc Half-year Report January 1 - June 30, 2026 (unaudited) | 173 | GlobeNewswire (Europe) | Company announcement, Helsinki, August 14, 2026 at 9 am (EEST)
NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 - JUNE 30, 2026 (UNAUDITED)
NEXSTIM CONTINUED ITS GROWTH AND STRENGHTENED ITS FINANCIAL POSITION
The... ► Artikel lesen | |
| 14.07. | Nexstim Oyj: Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor | 300 | GlobeNewswire (Europe) | Press Release, Helsinki, 14 July 2026 at 9 AM (EEST)
Nexstim Receives a New Order for Ten NBS 6 Systems from Distributor
Nexstim Plc ("Nexstim" or "Company") has received a new order for ten NBS 6 systems... ► Artikel lesen | |
| 13.05. | Nexstim Oyj: Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain Option Holders | 419 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 13 May 2026 at 09:05 AM (EEST)
Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain... ► Artikel lesen | |
| 28.04. | Nexstim Oyj: Nexstim Plc Business Update Q1 2026 | 464 | GlobeNewswire (Europe) | Press release, Helsinki, 28 April 2026 at 9 AM (EEST)
Nexstim Plc Business Update Q1 2026
Nexstim Plc ("Nexstim" or "Company") announces the key highlights of the Company's business operations during... ► Artikel lesen | |
| NEXSTIM Aktie jetzt für 0€ handeln | |||||
| 17.04. | Nexstim Oyj: Nexstim Plc establishes Restricted Share Unit plan for extended management team for earning periods 2026-2029 | 204 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 17 April 2026 at 9 AM (EEST)
Nexstim Plc establishes Restricted Share Unit plan for extended management team for earning periods 2026-2029
The Board of Directors of Nexstim... ► Artikel lesen | |
| 30.03. | Nexstim Oyj: Nexstim Plc: Resolutions of the Annual General Meeting | 208 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 30 March 2026 at 1:30 PM (EEST)
Nexstim Plc: Resolutions of the Annual General Meeting
Nexstim Plc ("Nexstim" or "Company") announces the following resolutions of the... ► Artikel lesen | |
| 23.03. | Nexstim Oyj: Nexstim's NBS System 6 gains FDA clearance for treatment of Obsessive Compulsive Disorder (OCD) | 395 | GlobeNewswire (Europe) | Press release, Helsinki, 23 March 2026 at 10:30 AM (EET)
Nexstim's NBS System 6 gains FDA clearance for treatment of Obsessive Compulsive Disorder (OCD)
Nexstim Plc ("Nexstim" or "Company") announces... ► Artikel lesen | |
| 26.02. | Nexstim Oyj: Nexstim Plc's Financial Statements Bulletin 2025 | 623 | GlobeNewswire (Europe) | Company announcement, Helsinki 26 February 2026 at 9 am (EET)
NEXSTIM PLC'S FINANCIAL STATEMENTS BULLETIN 2025
NEXSTIM ACCELERATED GROWTH AND ACHIEVED A PROFITABLE RESULT
January-December 2025
The... ► Artikel lesen | |
| 19.02. | Nexstim Oyj: Nexstim's NBS 6 system receives MDR certification in the EU for use in Post-Operative Rehabilitation | 257 | GlobeNewswire (Europe) | Press release, Helsinki, 19 February 2026 at 9 AM (EET)
Nexstim's NBS 6 system receives MDR certification in the EU for use in Post-Operative Rehabilitation
Nexstim Plc ("Nexstim" or "Company") has... ► Artikel lesen | |
| 16.02. | Nexstim Oyj: Nexstim Receives Clearance for its NBS 6 Diagnostics System in UAE | 604 | GlobeNewswire (Europe) | Press release, Helsinki, 16 February 2026 at 11:30 AM (EET)
Nexstim Receives Clearance for its NBS 6 Diagnostics System in UAE
Nexstim Plc ("Nexstim" or "Company") has received import clearance for... ► Artikel lesen | |
| 02.02. | Nexstim Oyj: Nexstim Receives System Order from Distributor in India | 384 | GlobeNewswire (Europe) | Press release, Helsinki, 2 February 2026 at 9 AM (EET)
Nexstim Receives System Order from Distributor in India
Nexstim Plc ("Nexstim" or "Company") has received an order for an NBS System 5 through... ► Artikel lesen | |
| 30.12.25 | Nexstim Oyj: US Customer Orders Two Nexstim NBS 6 Therapy Systems | 469 | GlobeNewswire (Europe) | Press release, Helsinki, 30 December 2025 at 9 AM (EET)
US Customer Orders Two Nexstim NBS 6 Therapy Systems
Nexstim Plc ("Nexstim" or "Company") has received an order for two NBS 6 therapy systems... ► Artikel lesen | |
| 23.12.25 | Nexstim Oyj: Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc. | 293 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 23 December 2025 at 9 AM (EET)
Inside information: Nexstim Plc Agrees on Next Phase of Exclusivity Agreement with Sinaptica Therapeutics, Inc.
Nexstim Plc ("Nexstim"... ► Artikel lesen | |
| 16.09.25 | Nexstim Oyj: Nexstim Receives NBS 5+ System Order from Therapy Customer in United States | 267 | GlobeNewswire (Europe) | Press release, Helsinki, 16 September 2025 at 9 AM (EEST)
Nexstim Receives NBS 5+ System Order from Therapy Customer in United States
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| VERU | 2,345 | +0,21 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| NYXOAH | 1,362 | 0,00 % | Cantor Fitzgerald reiterates Nyxoah stock Overweight rating at $6 | ||
| OPTOMED | 1,558 | -0,64 % | Optomed Oyj: Half-year report January - June 2026 | Optomed Plc Stock Exchange Release 14 August 2026 at 9.00, Helsinki
Optomed Plc: Half-year report January - June 2026
April - June 2026
Revenue decreased by 8.6 percent to EUR 3.5 (3.8) million.
Currency-adjusted... ► Artikel lesen | |
| MODULIGHT | 0,960 | -3,03 % | Modulight Oyj: Inside Information: Modulight has received a $1.5 million pilot production order from a U.S. neuroscience customer | Modulight Corporation | Inside Information | September 15, 2026 at 13:25:00 EEST
Modulight Corporation has received a $1.5 million pilot production purchase order from an existing U.S. venture customer... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 10,400 | +0,29 % | Alignment Healthcare USA, LLC: Alignment Health's Fifth Annual Survey Finds Seniors Falling Further Behind: Aging in Place Challenges Continue to Rise as Support Gaps Widen | ||
| FRESENIUS | 45,390 | -0,69 % | JPMORGAN stuft Fresenius SE auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Fresenius auf "Overweight" belassen. Die Experten Anchal Verma und David Adlington bleiben für die europäischen Medizintechnikunternehmen... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 38,870 | -0,31 % | JPMORGAN stuft Siemens Healthineers auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Siemens Healthineers auf "Overweight" belassen. Die Experten Anchal Verma und David Adlington bleiben für die europäischen Medizintechnikunternehmen... ► Artikel lesen | |
| GENEDX | 94,64 | 0,00 % | GeneDx: Starkes Wachstum trifft auf schwachen Forderungseinzug | ||
| FRESENIUS MEDICAL CARE | 39,780 | +0,56 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC auf "Underweight" belassen. Die Experten Anchal Verma und David Adlington bleiben für die europäischen Medizintechnikunternehmen wegen des... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 19,300 | 0,00 % | Oppenheimer reiterates Procept BioRobotics stock rating | ||
| BRIGHTSPRING HEALTH SERVICES | 58,84 | 0,00 % | Here's Why You Should Add BrightSpring Stock to Your Portfolio Now | ||
| HEARTFLOW | 48,280 | -0,10 % | Heartflow, Inc.: Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half | FUSION trial presented at ESC and published in Journal of the American College of Cardiology demonstrates adding non-invasive lesion-specific physiology resolves critical diagnostic uncertainty, supporting... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 13,065 | +0,04 % | LifeStance Health auf Morgan Stanley Konferenz: Wachstum und Margen im Fokus | ||
| AVEANNA HEALTHCARE | 14,325 | 0,00 % | Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen |
NEXSTIM OYJ gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -0,52 % bei einem Aktienkurs von 9,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXSTIM OYJ finden Sie auf Wallstreet Online.